Novel pharmaceutical composition for diagnosing fibrotic diseases

A pharmaceutical composition measuring asporin protein levels in blood samples addresses the challenge of early fibrotic disease diagnosis, providing a reliable and non-invasive method for detecting idiopathic pulmonary fibrosis and other fibrotic diseases, thereby improving prognosis and treatment timing.

WO2024237710A1PCT designated stage expired Publication Date: 2024-11-21UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006677
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for diagnosing fibrotic diseases, particularly idiopathic pulmonary fibrosis, are inadequate for early detection, leading to late-stage diagnosis and poor prognosis, as they lack effective biomarkers for reliable and timely identification.

Method used

Development of a pharmaceutical composition that measures the level of asporin protein or its encoding gene in blood samples, utilizing antibodies or aptamers for immunoassays, to detect fibrotic diseases with high accuracy and reliability, including idiopathic pulmonary fibrosis, through the identification of significantly increased asporin protein levels in patients.

Benefits of technology

Enables early and accurate diagnosis of fibrotic diseases, such as idiopathic pulmonary fibrosis, using non-invasive liquid biopsies, significantly improving detection reliability and potentially increasing survival rates by enabling timely treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006677_21112024_PF_FP_ABST
    Figure KR2024006677_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a method for predicting or diagnosing the occurrence of fibrotic diseases by measuring the level of asporin protein in the blood. Ultimately, the present invention can be advantageously used in a method for rapidly diagnosing fibrotic diseases in an initial stage with high reliability, on the basis of the first identification that an asporin protein present in an easily collectable blood (serum) sample can be used as a biomarker for fibrotic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Novel pharmaceutical composition for the diagnosis of fibrotic diseases

[0001] The present invention relates to a method for early and accurate diagnosis of fibrotic disease by measuring the level of asporin protein present in the blood of a subject, based on the first discovery that asporin (ASPN) protein significantly increases in the blood of a patient with fibrotic disease.

[0002] Most organs undergo an inflammatory response and healing process after tissue damage. However, in cases of continuous damage or irreparable stimuli, tissues undergo fibrosis during the healing process, leading to organ dysfunction. Meanwhile, a disease that typically causes fibrosis in the lungs is idiopathic pulmonary fibrosis (IPF). This disease is known to have a poor prognosis, with the onset mostly occurring between the ages of 50 and 70 and a five-year survival rate of only 20-30%. Patients with idiopathic pulmonary fibrosis often present at the hospital when their lung function has fallen below 70%, indicating that the disease is already in a severe stage. Therefore, the development of an early diagnosis method that is both accurate and accessible is urgently needed to actively promote treatment in the early stages of the disease and increase the survival rate.

[0003] Fibrosis is a regenerative or reactive process characterized by the formation and deposition of excessive fibrous connective tissue, which is a major etiological factor in various fibrotic diseases and chronic conditions. In particular, pulmonary fibrosis, although its precise mechanism remains unknown, is believed to be caused by excessive deposition of the extracellular matrix (ECM) and damage to abnormal alveolar epithelial cells. Normally, fibroblasts play a crucial role in wound healing and connective tissue formation. However, unregulated, excessive fibroblast expression can lead to the accumulation of excessive immune cells and ECM proteins in foci, leading to pathological conditions. Beyond these general mechanisms, the predictors and pathogenesis of pulmonary fibrosis remain elusive. Therefore, elucidating the precise molecular and biological mechanisms is crucial for the diagnosis and treatment of pulmonary fibrosis.

[0004] Accordingly, the present inventors have for the first time demonstrated that asporin protein significantly increases in the blood of patients with fibrosis, particularly pulmonary fibrosis, and through this, they aimed to develop a rapid and highly accurate method for early diagnosis of fibrotic diseases.

[0005] Numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.

[0006]

[0007] The present inventors have diligently researched and developed an efficient method for the early diagnosis of idiopathic pulmonary fibrosis (IPF), a highly prevalent, intractable disease worldwide with no effective treatment options except for lung transplantation. As a result, they have discovered for the first time that asporin protein expression is specifically increased not only in the lung tissue but also in the blood of patients with pulmonary fibrosis. This has enabled them to confirm that idiopathic pulmonary fibrosis can be detected with high reliability in the early stages of the disease through body fluid diagnosis, thereby completing the present invention.

[0008] Therefore, the purpose of the present invention is to provide a composition for diagnosing fibrotic disease.

[0009] Another object of the present invention is to provide a diagnostic kit comprising the diagnostic composition.

[0010] Another object of the present invention is to provide a method for providing information for diagnosing fibrotic disease.

[0011] Another object of the present invention is to provide a diagnostic device for a fibrotic disease, comprising: a measuring unit for measuring the expression level of Asporin (ASPN) protein or a gene encoding the same in a biological sample isolated from an individual; and a detection unit for outputting the presence or absence of a fibrotic disease from the expression level of the gene or the protein encoded by the same measured by the measuring unit. Other objects and advantages of the present invention will become more apparent from the detailed description, claims, and drawings below.

[0012]

[0013] According to one aspect of the present invention, the present invention provides a composition for diagnosing fibrotic disease, comprising as an active ingredient an agent for measuring the level of Asporin (ASPN) protein or a gene encoding them in blood.

[0014] The present inventors have devoted extensive research efforts to develop an efficient early diagnosis method for idiopathic pulmonary fibrosis (IPF), a highly prevalent, intractable disease worldwide with no effective treatment options except for lung transplantation. As a result, they have discovered for the first time that asporin protein expression is specifically increased not only in the lung tissue of patients with pulmonary fibrosis but also in the blood. This has enabled them to confirm that idiopathic pulmonary fibrosis can be detected with high reliability in the early stages of the disease through body fluid diagnosis, thereby completing the present invention.

[0015] In addition, there is a literature that reports that the expression level of intracellular asporin protein increases in pancreatic cancer (Lili Wang, Huanwen Wu, Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms, Cancer Letters, Volume 398, 2017, Pages 24-36, ISSN 0304-3835, https: / doi.org / 10.1016 / j.canlet.2017.04.001.), and asthma is associated with an increase in the expression level of intracellular asporin protein, but unlike patients with pulmonary fibrosis, there was no significant difference in the expression level of intracellular asporin protein (see Figure 3). Therefore, although an increase in the expression of asporin protein in tissues does not necessarily lead to an increase in the expression of asporin protein in the blood, the significant increase in asporin protein in the blood of patients with fibrosis can increase the speed and accuracy of early diagnosis methods for fibrotic diseases.

[0016] The term “asporin protein” as used herein refers to a protein encoded by the ASPN gene in humans, which belongs to the leucine-rich repeat (LRR) protein family associated with the cartilage matrix. The asporin protein may also be referred to as OS3, PLAP-1, PLAP1, or SLRR1C.

[0017] As used herein, the term "fibrotic disease" refers to all pathological conditions that involve the progression of fibrosis in pathological tissues and are directly or indirectly caused by such fibrosis. Furthermore, the term "fibrosis" refers to a disease in which fibrous connective tissue (components of the extracellular matrix, such as collagen and fibronectin) excessively accumulates within and around inflamed or damaged tissues, potentially resulting in permanent scarring, organ dysfunction, and ultimately death.

[0018] The term “diagnosis” as used herein includes determining an individual’s susceptibility to a particular disease, determining whether an individual currently has a particular disease, and determining a prognosis for an individual with a particular disease.

[0019] In this specification, the term “diagnostic composition” means a conventional mixture or device that includes a means for measuring the expression level of Asporin protein or a gene encoding it to determine whether a subject has a fibrotic disease or to predict the possibility of occurrence, and may also be expressed as a “diagnostic kit.”

[0020] According to the present invention, the gene encoding the asporin protein of the present invention also includes mRNA that can be translated into asporin.

[0021]

[0022] According to a specific embodiment of the present invention, the fibrotic disease of the present invention is selected from the group consisting of liver fibrosis, renal fibrosis, and pulmonary fibrosis.

[0023] The term “liver fibrosis” in the present invention refers to a symptom in which fibrous tissue proliferates due to chronic damage to the liver, and may be caused by various causes such as biliary fibrosis, post-necrotic scarring, and diffuse liver fibrosis.

[0024] The term “renal fibrosis” in the present invention refers to a disease characterized by tubulointerstitial fibrosis and glomerular sclerosis, and as a final sign of chronic kidney disease, renal fibrosis is characterized by excessive accumulation and deposition of extracellular matrix components.

[0025] The term “pulmonary fibrosis” in the present invention refers to a disease in which the lungs become fibrotic due to repeated damage and scarring of the lungs or lung tissue, and is accompanied by symptoms such as shortness of breath; dry cough; fatigue; weight loss; and nail clubbing.

[0026]

[0027] According to a specific embodiment of the present invention, the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

[0028] In the present invention, the term “idiopathic pulmonary fibrosis” refers to a progressive respiratory disease characterized by thickening and stiffening of lung tissue and formation of scar tissue, and is a type of chronic scarring lung disease characterized by gradual and irreversible decline in lung function, and is referred to as “idiopathic” because the clear cause is unknown.

[0029]

[0030] According to a specific embodiment of the present invention, the agent for measuring the level of asporin protein in the present invention is an antibody or an antigen-binding fragment thereof that specifically recognizes asporin protein; or an aptamer.

[0031] According to the present invention, the presence of asporin protein in blood can be detected using an immunoassay method utilizing antigen-antibody reactions, which can be used to analyze the presence of fibrotic diseases. This immunoassay can be performed using various immunoassay or immunostaining protocols developed in the past.

[0032] For example, when the method of the present invention is performed according to a radioimmunoassay method, a radioisotope (e.g., C 14 , I 125 , P 32 and S 35 ) can be used. In the present invention, the antibody that specifically recognizes the Asporin protein is a polyclonal or monoclonal antibody, and is preferably a monoclonal antibody.

[0033] The antibodies of the present invention can be produced by methods commonly practiced in the art, for example, the fusion method (Kohler and Milstein, European Journal of Immunology, 6:511-519 (1976)), the recombinant DNA method (U.S. Patent No. 4,816,567), or the phage antibody library method (Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. Mol. Biol., 222:58, 1-597 (1991)). General procedures for antibody production are described in detail in Harlow, E. and Lane, D., Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press, New York (1999).

[0034] By analyzing the intensity of the final signal from the immunoassay process described above, the onset or likelihood of developing idiopathic pulmonary fibrosis can be predicted. Specifically, if the signal for the asporin protein in an individual's sample is stronger than in a normal sample, the individual is considered to have progressed to, or is likely to develop, idiopathic pulmonary fibrosis.

[0035] As used herein, the term “antigen binding fragment” means a portion of a polypeptide in the overall structure of an immunoglobulin capable of binding an antigen, including, but not limited to, F(ab')2, Fab', Fab, Fv, and scFv.

[0036] In this specification, the term “specifically binding” has the same meaning as “specifically recognizing” and means that an antigen and an antibody (or a fragment thereof) specifically interact through an immunological reaction.

[0037] The present invention can also utilize aptamers that specifically bind to the above-described proteins instead of antibodies. As used herein, the term “aptamer” refers to a single-stranded nucleic acid (RNA or DNA) molecule or peptide molecule that binds to a specific target substance with high affinity and specificity. General information on aptamers is described in detail in Hoppe-Seyler F, Butz K, “Peptide aptamers: powerful new tools for molecular medicine”. J Mol Med. 78(8):426-30(2000); Cohen BA, Colas P, Brent R. “An artificial cell-cycle inhibitor isolated from a combinatorial library”. Proc Natl Acad Sci USA. 95(24):14272-7(1998).

[0038] In the present invention, markers used for diagnosing pulmonary fibrosis can be targets for diagnosing pulmonary fibrosis as proteins having the entire sequence, and even partial fragments of the asporin protein can be targets for diagnosing pulmonary fibrosis, and all types of protein or peptide fragment detection methods including the above-described protein measurement methods can be used.

[0039] According to a specific embodiment of the present invention, the measurement of the expression level of the Asporin protein present in the blood can be performed by Mass Spectrometry (MS). As used herein, the term “mass spectrometry” may also be referred to as “mass spectrometry” and refers to a method of analyzing an unknown compound by its mass. Mass spectrometry is performed by filtering, detecting, and measuring ions using the mass-to-charge ratio, m / z value, and generally, mass spectrometry includes the steps of (1) ionizing and charging a compound and (2) measuring the molecular weight of the charged compound and calculating the m / z value. The calculated m / z value is used as a reference to identify and quantify a target compound in a complex mixture. The mass spectrometry of the present invention can be performed by any type of mass spectrometry using the above-mentioned principle.

[0040]

[0041] According to a specific embodiment of the present invention, the agent for measuring the level of a gene encoding an asporin protein in the present invention is a primer or probe that specifically binds to a nucleic acid molecule of the gene.

[0042] In this specification, the term “nucleic acid molecule” has a meaning that comprehensively includes DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units in nucleic acid molecules, include not only natural nucleotides but also analogues in which sugar or base moieties are modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhl

[0043] The term "primer" as used herein refers to an oligonucleotide that acts as an initiation point for synthesis under conditions that induce the synthesis of a primer extension product complementary to a nucleic acid chain (template), i.e., the presence of nucleotides and a polymerization agent such as DNA polymerase, and conditions of suitable temperature and pH. Specifically, the primer is a single chain of deoxyribonucleotides. The primer used in the present invention may include naturally occurring dNMPs (i.e., dAMP, dGMP, dCMP, and dTMP), modified nucleotides, or non-natural nucleotides, and may also include ribonucleotides.

[0044] The primer of the present invention may be an extension primer that anneals to a target nucleic acid and forms a sequence complementary to the target nucleic acid by a template-dependent nucleic acid polymerase, which extends to a position to which an immobilized probe is annealed and occupies a portion to which the probe is annealed.

[0045] The extension primer used in the present invention includes a hybridizing nucleotide sequence complementary to a specific base sequence of a target nucleic acid, for example, genes used as markers in the present invention. The term “complementary” means that the primer or probe is sufficiently complementary to selectively hybridize to the target nucleic acid sequence under predetermined annealing or hybridization conditions, and includes both substantially complementary and perfectly complementary sequences, and specifically means perfectly complementary. As used herein, the term “substantially complementary sequence” includes not only a completely identical sequence, but also a sequence that is partially mismatched with the sequence to be compared, within a range that can anneal to a specific sequence and serve as a primer.

[0046] The primer must be sufficiently long to prime the synthesis of the extension product in the presence of a polymerization agent. The appropriate primer length depends on several factors, such as temperature, pH, and the primer source, but is typically 15-30 nucleotides. Shorter primer molecules generally require lower temperatures to form sufficiently stable hybrid complexes with the template. The design of such primers can be readily accomplished by those skilled in the art, using the target nucleotide sequence as a reference, and can be accomplished, for example, using a primer design program (e.g., PRIMER 3).

[0047] As used herein, the term "probe" refers to a linear oligomer having a natural or modified monomer or linkage comprising deoxyribonucleotides and ribonucleotides that can hybridize to a specific nucleotide sequence. Specifically, the probe is single-stranded for maximum efficiency in hybridization, and more specifically, is a deoxyribonucleotide. As the probe used in the present invention, a sequence that is perfectly complementary to a specific base sequence of genes used as markers in the present invention may be used, but a sequence that is substantially complementary may also be used as long as it does not interfere with specific hybridization. In general, since the stability of a duplex formed by hybridization tends to be determined by the identity of the terminal sequence, it is preferable to use a probe that is complementary to the 3'-end or 5'-end of the target sequence.

[0048] Suitable conditions for hybridization can be determined by referring to those disclosed in Joseph Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY (2001) and Haymes, BD, et al., Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, DC (1985).

[0049]

[0050] According to one aspect of the present invention, there is provided a method for providing information necessary for the diagnosis of a fibrotic disease, comprising the step of measuring the expression level of Asporin (ASPN) protein or a gene encoding them in a biological sample isolated from an individual.

[0051] The present inventors have discovered for the first time a positive correlation between the expression level of the Asporin (ASPN) protein or the gene encoding it in the blood and the risk of developing a fibrotic disease. Therefore, if the Asporin protein or the gene encoding it is highly expressed within an individual or in a biological sample isolated from the individual, the individual is considered to have developed a fibrotic disease or is at high risk of developing it in the future.

[0052] The types and characteristics of fibrotic diseases related to the method for providing information necessary for diagnosing fibrotic diseases of the present invention have already been described above, so description thereof is omitted to avoid excessive duplication.

[0053] In this specification, the term “high expression” means a case where the expression level of a gene or a protein encoded by the gene is significantly higher than that of a control group or a normal group, and specifically means a case where the expression level increases by about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50% or more, or about 60% or more compared to the control group or normal group, but does not exclude a range beyond this.

[0054] As used herein, the term “subject” refers to a subject that provides a sample for measuring the expression level of asporin protein or a gene encoding them, and ultimately becomes the subject of analysis for the development of a fibrotic disease. The subject includes, without limitation, a human, a mouse, a rat, a guinea pig, a dog, a cat, a horse, a cow, a pig, a monkey, a chimpanzee, a baboon, or a rhesus macaque, and is specifically a human. Since the composition of the present invention provides information for predicting not only the current development of a fibrotic disease but also the genetic risk of developing a fibrotic disease in the future, the subject of the present invention may be a patient with a fibrotic disease or a healthy subject that has not yet developed a fibrotic disease.

[0055] The term "biological sample" as used herein refers to any sample obtained from a mammal, including a human, that contains cells expressing the aforementioned gene or proteins produced by the expression of the aforementioned gene, including, but not limited to, tissues, organs, cells, or cell cultures. More specifically, the biological sample may be blood. Most specifically, it may be serum.

[0056]

[0057] According to a specific embodiment of the present invention, the biological sample of the present invention is blood.

[0058] The term “blood” in this specification means “whole blood,” which includes plasma and serum.

[0059] The term "whole blood" as used herein generally refers to blood composed of uncoagulated plasma and cellular components. Plasma comprises approximately 50 to 60% of the volume of whole blood, and cellular components (e.g., red blood cells, white blood cells, or platelets) may comprise approximately 40 to 50%.

[0060] The term “plasma” as used herein refers to the liquid component of blood, which functions as a transport medium in supplying nutrients to the cells and organs of the body.

[0061] According to a specific embodiment of the present invention, the biological sample of the present invention is serum.

[0062] The term “serum” used in this specification refers to a pale yellow liquid collected from blood, and more specifically, it refers to a pale yellow body fluid component that remains when a red clot is removed after blood is collected and left to stand, as the fluidity of the blood decreases.

[0063] According to the present invention, it is possible to diagnose a fibrotic disease using an asporin protein or a gene encoding the same, and the diagnosis can be made through a liquid biopsy using a patient-derived body fluid such as blood as a biological sample. This liquid biopsy method has the advantage of being non-invasive compared to conventional tissue biopsy procedures, thereby minimizing patient pain, and also has the advantage of obtaining information on the fibrotic disease more quickly.

[0064] According to another embodiment of the present invention, the present invention relates to a diagnostic kit for fibrotic disease comprising the diagnostic composition of the present invention.

[0065] In the present invention, the "kit" refers to a tool that can evaluate the expression level of a biomarker by labeling a probe or antibody that specifically binds to a biomarker component with a detectable label. It includes not only direct labeling of a detectable substance related to a probe or antibody through reaction with a substrate, but also indirect labeling in which a chromogenic label is conjugated through reactivity with another directly labeled reagent. It may include a chromogenic substrate solution, a washing solution, and other solutions that react with the label to develop a color, and may be manufactured including the reagent components used. In the present invention, the kit may be a kit that includes the essential elements required for performing RT-PCR, and may include, in addition to each primer pair specific for a marker gene, a test tube, a reaction buffer, deoxynucleotides (dNTPs), Taq polymerase, reverse transcriptase, DNase, RNase inhibitor, sterile water, etc. In addition, the kit may be a kit for detecting genes for cancer diagnosis that includes the essential elements required for performing a DNA chip. The DNA chip kit comprises a substrate to which a cDNA corresponding to a gene or a fragment thereof is attached as a probe, and the substrate may include a cDNA corresponding to a quantitative control gene or a fragment thereof. The kit of the present invention is not limited thereto, as long as it is known in the art.

[0066] In the present invention, the kit may be an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or an MRM (Multiple reaction monitoring) kit.

[0067] The kit of the present invention may further comprise one or more other component compositions, solutions, or devices suitable for the analysis method. For example, the kit of the present invention may further comprise essential elements necessary for performing a reverse transcription polymerase reaction. The reverse transcription polymerase reaction kit comprises a pair of primers specific for a gene encoding a marker protein. The primers are nucleotides having a sequence specific for the nucleic acid sequence of the gene, and may have a length of about 7 bp to 50 bp, more preferably about 10 bp to 30 bp. It may also comprise a primer specific for the nucleic acid sequence of a control gene. In addition, the reverse transcription polymerase reaction kit may comprise a test tube or other appropriate container, a reaction buffer (with various pH and magnesium concentrations), deoxynucleotides (dNTPs), an enzyme such as Taq polymerase and reverse transcriptase, DNase, RNase inhibitor DEPC-water, sterile water, etc.

[0068] Additionally, the diagnostic kit for fibrotic diseases of the present invention may include essential elements necessary for performing a DNA chip. The DNA chip kit may include a substrate to which cDNA or oligonucleotides corresponding to a gene or fragment thereof are attached, and reagents, preparations, enzymes, etc. for producing a fluorescently labeled probe. The substrate may also include cDNA or oligonucleotides corresponding to a control gene or fragment thereof.

[0069] In addition, the diagnostic kit for fibrotic diseases of the present invention may include the essential elements necessary for performing an ELISA. The ELISA kit includes an antibody specific for the protein. The antibody is an antibody with high specificity and affinity for the marker protein and little cross-reactivity with other proteins, and may be a monoclonal antibody, a polyclonal antibody, or a recombinant antibody. The ELISA kit may also include an antibody specific for a control protein. In addition, the ELISA kit may include reagents capable of detecting the bound antibody, such as a labeled secondary antibody, chromophores, an enzyme (e.g., conjugated to the antibody), and its substrate or other substances capable of binding to the antibody.

[0070] In the present invention, a fixative for the antigen-antibody binding reaction may be a nitrocellulose membrane, a PVDF membrane, a well plate synthesized from polyvinyl resin or polystyrene resin, a glass slide glass, etc., but is not limited thereto.

[0071] In addition, in the present invention, the label of the secondary antibody is preferably a conventional chromogen that undergoes a color development reaction, and labels such as fluorescein and dyes such as HRP (horseradish peroxidase), alkaline phosphatase, colloid gold, FITC (poly L-lysine-fluorescein isothiocyanate), and RITC (rhodamine-B-isothiocyanate) can be used, but are not limited thereto.

[0072] In addition, in the present invention, it is preferable to use a chromogenic substrate for inducing color development according to a marker that undergoes a color development reaction, and TMB (3,3',5,5'-tetramethyl bezidine), ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)], OPD (o-phenylenediamine), etc. can be used. At this time, it is more preferable that the chromogenic substrate is provided in a state dissolved in a buffer solution (0.1 M NaAc, pH 5.5). A chromogenic substrate such as TMB is decomposed by HRP used as a marker of a secondary antibody conjugate to generate a chromogenic precipitate, and the presence or absence of the marker proteins is detected by visually confirming the degree of deposition of this chromogenic precipitate.

[0073] In the present invention, the washing solution preferably contains a phosphate buffer solution, NaCl, and Tween 20, and a buffer solution (PBST) composed of 0.02 M phosphate buffer solution, 0.13 M NaCl, and 0.05% Tween 20 is more preferred. After the antigen-antibody binding reaction, the washing solution reacts the secondary antibody with the antigen-antibody complex, and then an appropriate amount is added to the fixative and washed 3 to 6 times. The reaction stopping solution can preferably be a sulfuric acid solution (H2SO4).

[0074] According to another embodiment of the present invention, the present invention relates to a diagnostic device for fibrotic diseases.

[0075] The diagnostic device of the present invention relates to a diagnostic device for a fibrotic disease, comprising: a measuring unit for measuring the expression level of Asporin (ASPN) protein or a gene encoding the same in a biological sample separated from an individual; and a detection unit for outputting the presence or absence of a fibrotic disease from the expression level of the gene or the protein encoded by the same measured by the measuring unit.

[0076]

[0077] The features and advantages of the present invention are summarized as follows:

[0078] (a) The present invention provides a method for predicting or diagnosing the occurrence of fibrosis by measuring the level of asporin protein in blood.

[0079] (b) The present invention can be usefully applied to a method for rapidly and reliably diagnosing fibrotic diseases at an early stage by first elucidating that asporin protein present in easily collected blood (serum) samples can be used as a biomarker for fibrotic diseases.

[0080]

[0081] Figure 1a is a picture showing the results of co-immunofluorescence analysis on lung section slides (lung tissue) of patients with pulmonary fibrosis. Green represents ASPN, and red represents αSMA. Figure 1b is a picture showing the results of co-immunofluorescence analysis in the control group and IPF patients as a bar graph. Figure 1c is a picture showing the results of immunohistochemical examination on PBS (vehicle control), bleomycin-treated (BLM), wild-type (WT), and TGF-β-overexpressing mice (TGF-β TG mouse). Figure 1d is a picture showing the results of immunohistochemical examination on the control group, bleomycin-treated group, and the control group and TGF-β-overexpressing mice as a bar graph.

[0082] Figure 2 is a graph comparing the levels of mRNA encoding asporin protein between patients with idiopathic pulmonary fibrosis (IPF) and healthy controls (Healthy).

[0083] Figure 3a is a graph comparing the expression levels of asporin in the serum of patients with idiopathic pulmonary fibrosis (IPF) and controls. Figure 3b is a graph comparing the expression levels of asporin in the serum of patients with fatty liver disease and controls. Figure 3c is a graph comparing the expression levels of asporin in the serum of patients with pancreatic cancer and controls. Figure 3d is a graph comparing the expression levels of asporin in the serum of patients with asthma and controls.

[0084]

[0085] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0086]

[0087] Example

[0088] Experimental and analytical methods

[0089] Co-immunofluorescence

[0090] Lung section slides were rehydrated through a graded alcohol series of increasing concentrations, followed by antigen retrieval in 10 mM sodium citrate. The following primary antibodies were used: house-made monoclonal asporin α-SMA (Abcam, Cambridge, MA, USA) as an asporin antibody.

[0091] All secondary antibodies used were Alexa Fluor-coupled antibodies. After staining, slides were mounted with mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; Abcam, Cambridge, MA, USA) and stored at 4°C in the dark. Slides were imaged and analyzed using a Zeiss LSM780 confocal microscope (Carl Zeiss, Oberkochen, Germany).

[0092]

[0093] laboratory animals

[0094] Mice were housed in a specific pathogen-free animal facility with controlled temperature and humidity under a 12-h light / 12-h dark cycle. Before bleomycin (BLM) administration, 8-week-old mice were injected with 10 mg / kg tamoxifen (Merck, Darmstadt, Germany) three times a week for 1 week. Mice were anesthetized with an intraperitoneal injection of Zoletil 50 (30 mg / kg) and Rompun (10 mg / kg). Mice were injected intratracheally with PBS (vehicle control) or 4 mg / kg BLM (Santa Cruz Biotechnology, Dallas, TX, USA). An average of eight mice were used in each group.

[0095] To induce TGF-β1 expression in TGF-β1-TG mice, adult transgenic mice (8–12 weeks old) were provided with drinking water containing 0.5 mg / mL doxycycline (Merck, Darmstadt, Germany) in 2% sucrose for 4 weeks ("TGF-β overexpression in various tissues induces marked fibrotic changes" Transforming growth factor-β in tissue fibrosis, Nikolaos G. Frangogiannis, J Exp Med. 2020 Mar 2; 217(3): e20190103. Doi: 10.1084 / jem.20190103). The doxycycline-containing water was replaced three times a week.

[0096]

[0097] Immunostaining

[0098] To prepare for immunohistochemistry (IHC), lung section slides were rehydrated through a graded alcohol series of increasing concentrations, followed by antigen retrieval in 10 mM sodium citrate. The IHC staining protocol included sequential application of peroxidase blocking reagent, primary antibody (overnight), secondary antibody (1 hour), and horseradish peroxidase conjugated to a polymer backbone, followed by visualization using 3,3'-diaminobenzidine tetrahydrochloride (DAB) and chromogen reagent with hydrogen peroxide substrate (Dako, Santa Clara, CA, USA). The intensity of asporin protein was calculated using ImageJ.

[0099]

[0100] ELISA analysis

[0101] The amount of protein was measured using the Asporin ELISA kit (MybiosourceMBS760704) in 20 μl of serum from patients with idiopathic pulmonary fibrosis (IPF), fatty liver disease, pancreatic cancer, and asthma. The ELISA was performed according to the manual included in the kit, and color development was detected at 470 nm.

[0102]

[0103] Experimental results

[0104] Asporin mRNA expression was significantly increased in patients with idiopathic pulmonary fibrosis.

[0105] As a result of investigating the gene expression of aspirin using NCBI GEO data (GSE110147 data), it was confirmed that aspirin mRNA was significantly increased in the IPF patient group compared to the normal group.

[0106]

[0107] Asporin expression was specifically increased in patients with idiopathic pulmonary fibrosis.

[0108] Among patients with idiopathic pulmonary fibrosis (IPF), fatty liver disease, pancreatic cancer, and asthma, we observed a specific increase in asporin levels in the blood of patients with idiopathic pulmonary fibrosis. In conclusion, we concluded that a certain level of asporin elevation could be used as a diagnostic tool for pulmonary fibrosis.

[0109]

[0110] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A composition for diagnosing fibrotic disease, comprising as an active ingredient a preparation for measuring the level of asporin (ASPN) protein or a gene encoding them in the blood.

2. A composition according to claim 1, characterized in that the fibrotic disease is a disease selected from the group consisting of liver fibrosis, renal fibrosis, and pulmonary fibrosis.

3. A composition according to claim 2, characterized in that the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

4. A composition characterized in that, in the first paragraph, the agent for measuring the level of the asporin protein is an antibody or an antigen-binding fragment thereof that specifically recognizes the asporin protein; or an aptamer.

5. A composition according to claim 1, wherein the agent for measuring the level of the gene encoding the asporin protein is a primer or probe that specifically binds to a nucleic acid molecule of the gene.

6. A method for providing information necessary for diagnosing a fibrotic disease, comprising a step of measuring the expression level of Asporin (ASPN) protein or a gene encoding them in a biological sample isolated from an individual.

7. A method according to claim 6, characterized in that the fibrotic disease is a disease selected from the group consisting of liver fibrosis, renal fibrosis, and pulmonary fibrosis.

8. A composition according to claim 7, characterized in that the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

9. A method according to claim 6, characterized in that the biological sample is blood.

10. A method according to claim 9, characterized in that the biological sample is serum.

11. A diagnostic kit comprising a diagnostic composition according to any one of claims 1 to 6.

12. In paragraph 11, The above kit is a diagnostic kit, which is an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or an MRM (Multiple reaction monitoring) kit.

13. A measuring unit for measuring the expression level of Asporin (ASPN) protein or a gene encoding them in a biological sample separated from an object; and A diagnostic device for fibrotic disease, comprising a detection unit that outputs the presence or absence of a fibrotic disease from the expression level of a gene or a protein encoded by the gene measured in the above measurement unit.

14. In paragraph 13, A diagnostic device, wherein the fibrotic disease is at least one selected from the group consisting of liver fibrosis, renal fibrosis, and pulmonary fibrosis.

15. A diagnostic device according to claim 15, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

16. A diagnostic device according to claim 13, wherein the biological sample is blood.

17. A diagnostic device according to claim 13, wherein the biological sample is serum.

Citation Information

Patent Citations

  • Diagnosis of osteoarthritis by determination of asporin RNA levels

    US7906278B2

  • Method of modulating a fibrotic condition

    WO2021141733A1

  • KR20240041833A